Proceeds will be used to strengthen awareness for the patient benefits of bio-integrative OSSIOfiber® implants and accelerate new product platforms into the major orthopedic fixation markets
October 17, 2022 10:00 AM Eastern Daylight Time
WOBURN, Mass.–(BUSINESS WIRE)–OSSIO, Ltd., a fast-growing orthopedic fixation technology company, announced today that it has closed $38.5 million in Series C financing. Along with the participation of current shareholders, the round was led by MVM Partners, a Boston- and London-based growth equity firm investing in innovative, commercial stage healthcare companies that address high unmet medical needs.
“We are delighted to have secured this level of interest and commitment from such an experienced and distinguished medical technology investment firm,” said OSSIO’s chief executive officer, Brian Verrier. “The additional funding will enable us to accelerate further adoption of OSSIOfiber® Intelligent Bone Regeneration Technology by orthopedic and podiatric surgeons in the United States. Specifically, we intend to use these funds to fortify new product development, sales force expansion, patient outreach and medical education.”
All OSSIO implants are made with OSSIOfiber Intelligent Bone Regeneration Technology, a breakthrough in fixation material that provides the first credible solution to the shortcomings of permanent metal hardware, conventional resorbable and allograft implants, combining unparalleled mechanical strength and natural bone healing in a non-permanent implant. Made from a proprietary mineral fiber matrix held together by a naturally degradable polymer, the technology features bio-integrative material properties that provide surgeons with a more biologically friendly way to restore patient stability and mobility while leaving nothing permanent behind.
Designed for rapid bone in-growth, regeneration and replacement, OSSIOfiber Intelligent Bone Regeneration Technology is a first-of-its-kind implant material stronger than cortical bone. OSSIOfiber is engineered to provide the strength required for functional fixation and allows for full integration into the native anatomy without adverse biological response. OSSIOfiber implants utilize existing reimbursement and surgical techniques.
More than 10,000 OSSIOfiber implants have already been used in orthopedic surgeries since their commercial introduction in 2019.
“We believe that OSSIO’s novel bio-integrative technology has the potential to transform the orthopedic fixation market,” said MVM’s Dr. Stephen Reeders. “We are excited to support the company’s mission to improve patient outcomes across a broad range of procedures.”
Dr. Reeders and his MVM colleague Dr. Kevin Cheng join OSSIO’s board of directors as part of this financing.
OSSIO is an orthopedic fixation company committed to transforming the orthopedic experience for patients, physicians and payors. Founded in 2014, its vision is to provide the first credible replacement to metal implants in the multibillion-dollar global orthopedic fixation market with its OSSIOfiber Intelligent Bone Regeneration Technology. OSSIO’s development headquarters is located in Caesarea, Israel, and its US headquarters is in Woburn, MA. For more information on the company, visit www.ossio.io.
Forward-looking statements contained herein are based on estimates and assumptions of OSSIO management and are believed to be reasonable, though they are inherently uncertain and difficult to predict.
About MVM Partners
MVM has invested in high growth healthcare businesses since 1997. The firm has a broad, global investment outlook spanning medical technology, pharmaceuticals, diagnostics, digital health, and other sectors of healthcare.
GT Medical Technologies Names Per Langoe As CEO
February 20, 2024
Full release here: GT Medical Technologies, Inc. Names Per Langoe As CEO
MVM invests in icotec
January 24, 2024
ALTSTAETTEN, Switzerland and EAST HARTFORD, Conn., Jan. 24, 2024 /PR Newswire/ — icotec ag, the leading company in the field of innovative spinal […]
MVM invests in Gynesonics
November 1, 2023
REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) — Gynesonics® Inc., a women’s healthcare company focused on the development of […]
SkyCell Featured in TechCrunch
October 31, 2023
Full release here: SkyCell raises $57M at a $600M valuation to build smart containers for pharmaceutical transport | TechCrunch
MVM invests in BioProtect
September 27, 2023
TZUR IGAL, Israel, Sept. 27, 2023 /PRNewswire/ — BioProtect Ltd, a private Med Tech company focused on providing innovative, biodegradable spacing solutions, announced today the […]
VitalConnect Secures over $30 Million in Oversubscribed Series F Financing
July 18, 2023
SAN JOSE, Calif.–(BUSINESS WIRE)–VitalConnect®, Inc., a leader in remote and in-hospital wearable biosensor technology, today announced closing on an oversubscribed […]
MVM invests in CurvaFix
July 14, 2023
BELLEVUE, Wash.–(BUSINESS WIRE)–CurvaFix, Inc., a developer of medical devices to repair fractures in curved bones, today announced the close of […]
Vertos Medical Secures $26 Million to Expand Commercialization Efforts and Develop Breakthrough Treatments for Chronic Low Back Pain
June 7, 2023
ALISO VIEJO, Calif., June 7, 2023 /PRNewswire/ — Vertos Medical Inc., a leader in the development of innovative, minimally invasive treatments for […]
eXmoor pharma completes $35 million Series A to expand cell and gene therapy manufacturing capabilities
May 30, 2023
New GMP facility to complete eXmoor’s transition from consultancy to one-stop global cell and gene therapy partner Bristol, UK, May […]